发表论文

· 第一基金标注文章

[1] Zhou, J., J. Xu, Z. Feng, et al., A longitudinal analysis of the relationship between emotional symptoms and cognitive function in patients with major depressive disorder. Psychological Medicine, 2025. 55.DOI: 10.1017/s0033291725001011.

[2] Zhou, J., X. Wang, R. Wang, et al., Efficacy and Safety of Morinda Officinalis Oligosaccharides Combined with Probiotics as a Therapeutic Strategy for Major Depressive Disorder with Gastrointestinal Symptoms: A Randomized, Double-Blind, Controlled Clinical Trial. Neuropsychiatric Disease and Treatment, 2025. Volume 21: 2251-2264.DOI: 10.2147/ndt.S534858.

[3] Liu R, Hou X, Liu S, Zhou Y, Zhou J, Qiao K, Qi H, Li R, Yang Z, Zhang L, Cui J, Jin C*, Yu A*, Wang G*. Predicting antidepressant response via local-global graph neural network and neuroimaging biomarkers. NPJ Digit Med. 2025 Aug 12;8(1):515.

[4] Zang Z, Qiao K, Chen X, Zhou JJ, Yang Z, Wang G*. Divergent Longitudinal Trajectories and Neurotransmitter Associations of Striatal Subparcellation Spontaneous Activity in Major Depressive Disorder. Biol Psychiatry Glob Open Sci. 2025 May 2;5(5):100523.

[5] Jin Y, Gu R, Feng C, Zhang C, Zhou Y*. Cooperation patterns in depression: Insights from a meta-analysis of responsive and expressive social interactive paradigms. Clin Psychol Rev. 2025;120:102624. doi:10.1016/j.cpr.2025.102624.

[6] Wang Y, Zhou J, Chen X, Liu R, Zhang Z, Feng Y, Zhou Y*, Wang G*. Role of baseline resting-state functional connectivity of the nucleus accumbens subregions in antidepressant treatment in major depressive disorder. Neuroimage Clin. 2025 Jul 8;48:103842.

[7] Jin J, Wang Y, Liang S, Fan Q, Li M, Zhang L, Cao Y, Wang Z, Li R, Liu H, Zhou Y, Wang G. Effects of individualized rTMS on functional connectivity related to the default mode network and frontal-parietal network in major depressive disorder: exploratory analysis of a randomized controlled trial. Neuroimage Clin. 2025 Nov 7;48:103902.

[8] Lyu N, Zhao Q, Liu D, Zhou J, Zhu X, Qi H, Wang H, Liu M, Wei M, Zhang C, Zhang L, Yang J, Wang G, Juruena M, Young AH.  Genome-Wide Association and DNA Methylation Analyses of SSRI Treatment Response in Major Depressive Disorder. BMC Psychiatry, 2025, 25:1030. DOI: 10.1186/s12888-025-07502-y

[9] Feng Z, Zhou J, Liu R, Xiao L, Feng Y, Li R, Li X, Zhang X, Liu J, Wang G, Zhou J. Interrelationships Among Personality Traits, Depressive Symptoms, Childhood Abuse, and Social Disability. Depress Anxiety. 2025 Oct 1;2025:2250192. doi: 10.1155/da/2250192.

[10]  Zhou J, Wang X, Feng L, Feng Y, Xiao L, Chen X, Feng Z, Wang G, Zhou J. Group-Based Trajectory Analysis of Depressive Symptoms in Patients Treated with Antidepressants in Chinese Cohort Studies. Braz J Psychiatry. 2025 Oct 31. doi: 10.47626/1516-4446-2025-4560..

[11] Jin Y, Zheng D, Gu R, Fan Q, Dietz M, Wang C, Li X, Chen J, Hu Y, Zhou Y. Substantial Heritability Underlies Fairness Norm Adaptation Capability and its Neural Basis. Adv Sci (Weinh). 2025 Mar;12(9):e2411070. doi: 10.1002.

[12] Li HX, Chen X, Wang ZH, Lu B, Liao YF, Li XY, Wang YW, Liu YS, Castellanos FX, Yan CG*. Characterizing human spontaneous thoughts and its application in major depressive disorder. J Affect Disord. 2024 Nov 15;365:276-284.

[13] Zhou J, Liu R, Zhou J, Liu J, Zhou Y, Yang J, Wang G. Elevated VCAM-1 levels in peripheral blood are associated with brain structural and functional alterations in major depressive disorder. J Affect Disord. 2024 Feb 15;347:584-590.

[14] Hou, X., Liu, R., Zhou, Y. et al. Shared and unique alterations of large-scale network connectivity in drug-free adolescent-onset and adult-onset major depressive disorder. Transl Psychiatry 14, 255 (2024).

[15] Zhou, J., J. Zhou, Y. Feng, et al., The novel subtype of major depressive disorder characterized by somatic symptoms is associated with poor treatment efficacy and prognosis: A data-driven cluster analysis of a prospective cohort in China. Journal of Affective Disorders, 2024. 347: 576-583.DOI: 10.1016/j.jad.2023.12.005.

[16] Zhou, J., J. Zhou, Z. Feng, et al., Identifying the core residual symptom in patients with major depressive disorder using network analysis and illustrating its association with prognosis: A study based on the national cohorts in China. Gen Hosp Psychiatry, 2024. 87: 68-76.DOI: 10.1016/j.genhosppsych.2024.01.012.

[17] Zhou, J., D. Li, F. Ye, et al., Effect of add-on transcranial alternating current stimulation (tACS) in major depressive disorder: A randomized controlled trial. Brain Stimul, 2024. 17(4): 760-768.DOI: 10.1016/j.brs.2024.06.004.

[18] Xie P, Zhou X, Li Y, Wu J, Zhang H, Huang Y, Tan X, Wen L, Olasunkanmi OI, Zhou J, Sun Z, Liu M, Zhang G, Wang Y, Xie P, Yang J, Zheng P. Gut microbial CAZymes markers for depression. Transl Psychiatry. 2024 Mar 5;14(1):135.

[19] Sun Z, Zhang B, Zhou J, Luo Y, Zhu X, Wang Y, He Y, Zheng P, Zhang L, Yang J, Wang G. Integrated Single-Cell RNA-seq and ATAC-seq Reveals Heterogeneous Differentiation of CD4+ Naive T Cell Subsets is Associated with Response to Antidepressant Treatment in Major Depressive Disorder. Adv Sci (Weinh). 2024 Aug;11(30):e2308393.

[20] Wang Y, Wang C, Zhou J, Chen X, Liu R, Zhang Z, Feng Y, Feng L, Liu J, Zhou Y, Wang G. Contribution of resting-state functional connectivity of the subgenual anterior cingulate to prediction of antidepressant efficacy in patients with major depressive disorder. Transl Psychiatry. 2024 Oct 1;14(1):399.

[21] Wang Y, Zhou J, Chen X, Liu R, Zhang Z, Feng L, Feng Y, Wang G, Zhou Y. Effects of escitalopram therapy on effective connectivity among core brain networks in major depressive disorder. J Affect Disord. 2024, 350:39-48.

[22] Zhou Y, Chen X, Gu R, Xiang YT, Hajcak G, Wang G. Personalized identification and intervention of depression in adolescents: A tertiary-level framework. Sci Bull (Beijing). 2024 Apr 15;69(7):867-871.

[23] Yan, CG.*, Wang, XD., Lu, B., Deng, ZY, Gao, QL. (2024). DPABINet: A toolbox for brain network and graph theoretical analyses. Science Bulletin.

[24] Lu B., Chen X, Castellanos, FX., Thompson, P.M., Zuo, X.-N., Zang, Y.-F., Yan, C.-G.*. (2024). The power of many brains: Catalyzing neuropsychiatric discovery through open neuroimaging data and large-scale collaboration. Science Bulletin.

[25] Wang, Y.W., Chen, X., Yan, C.G.* (2023). Comprehensive evaluation of harmonization on functional brain imaging for multisite data-fusion. Neuroimage, 120089.

[26] Li, H.X., Lu, B., Wang, Y.W., Li, X.Y., Chen, X., Yan, C.G.* (2023). Neural representations of self-Generated thought during think-aloud fMRI. Neuroimage, 119775.

[27] Xiao, C., J. Zhou, A. Li, et al., Esketamine vs Midazolam in Boosting the Efficacy of Oral Antidepressants for Major Depressive Disorder. JAMA Network Open, 2023. 6(8).DOI: 10.1001/jamanetworkopen.2023.28817.

[28] Zhou J, Xu J, Liu R, Qi H, Yang J, Guo T, Zhou J, Zhu X, Zhang L, Chen X, Lyu N, Feng Z, Zhang G, Liu M, Wang W, Wang Y, Zhang Z, Xiao L, Feng Y, Wang G. A prospective cohort study of depression (PROUD) in China: rationale and design. Curr Med (Cham). 2023;2(1):1.

[29] Wang Y, Zhou J, Ye J, Sun Z, He Y, Zhao Y, Ren S, Zhang G, Liu M, Zheng P, Wang G, Yang J. Multi-omics reveal microbial determinants impacting the treatment outcome of antidepressants in major depressive disorder. Microbiome. 2023 Aug 28;11(1):195.

[30] Lu, B., Li, H.-X., Chang, Z.-K., Li, L., Chen, N.-X., Zhu, Z.-C., Zhou, H.-X., Li, X.-Y., Wang, Y.-W., Cui, S.-X., Deng, Z.-Y., Fan, Z., Yang, H., Chen, X., Thompson, P.M., Castellanos, F.X., Yan, C.G.* (2022). A practical Alzheimer’s disease classifier via brain imaging-based deep learning on 85,721 samples. Journal of Big Data, 9(1), 101.

[31] Yushan Wu, Shi Qiao, Jitao Zhong, Lu Zhang, Juan Wang, Bin Hu, Hong Peng*. FNIRS-based energy landscape analysis to signify brain activity dynamics of individuals with depression. CNS Neuroscience & Therapeutics, 2024, Vol.30(11). DOI: 10.1111/cns.70139.

[32] Lu Zhang, Jitao Zhong, Qinglin Zhao, Shi Qiao, Yushan Wu, Bin Hu*, Sujie Ma, Hong Peng*. Sparse discriminant manifold projections for automatic depression recognition. Neurocomputing, 2025, Vol. 614(21):128765.   

[33] Shi Qiao, Jitao Zhong, Lu Zhang, Hele Liu, Jiangang Li, Hong Peng, Bin Hu.  Robust semi-supervised extraction of information using functional near-infrared spectroscopy for diagnosing depression. Biomedical Signal Processing and Control, 2025, Vol.105:107571.

[34] Hele Liu, Jinzhou Zhu, Jitao Zhong,  Shi Qiao,  Lu Zhang,  Jiangang Li, Bin Hu*, Sujie Ma, Hong Peng*.  Exploring Functional Near-Infrared Spectroscopy and Transfer Learning for Discriminating Major Depressive Disorder and Generalized Anxiety Disorder.  Biomedical Signal Processing and Control, 2025, Vol.110: 108070.

[35] Yushan Wu, Jitao, Liu, Lu Zhang, Hele Liu, Shuai, Shao, Bin Hu, Hong, Peng. Locality-constrained robust discriminant non-negative matrix factorization for depression detection: An fNIRS study. Neurocomputing, 2025, Vol.617: 128887.

（3）获得软件著作权：

[1] 抑郁症知晓状况及健康教育干预平台V1.0（2025SR1697628）

[2] 安定医院精神疾病数据资源中心系统V1.0（登记号:2025SR0195251）

[3] 安定医院精神疾病临床队列数据质控系统V1.0（登记号:2025SR0195270）

[4] 安定医院精神疾病队列访视预约系统V1.0（登记号: 2025SR0195266）

[5] 安定医院精神疾病临床研究电子数据采集方案编辑系统V1.0（登记号:2025SRO195272）

[6] 抑郁症量化治疗决策系统【简称：抑郁症量化治疗系统】（2023SR0525278）

[7] 临床大数据生命周期管理系统V1.0（2023SR0535483）

[8] 临床大数据平台管理系统V1.0（2023SR0535544）

[9] 精神心理疾病临床研究平台（2024SR0302626）

[10] 精神心理疾病资源共享管理平台V1.0（2024SR0375840）

[11] 精神心理疾病受试者综合管理平台V1.0(2024SR0656874)

[12] 精神疾病患者随访管理平台【标准版】V1.0(2024SR0392612)

（4）申请发明专利：

[1] TMS治疗中针对心境障碍和焦虑障碍的控制处理方法（CN119303242B）

[2] 针对心境障碍和焦虑障碍实现TMS治疗的处理方法（申请号：CN119303241B）

[3] 检测试剂、检测试剂盒及酶活的检测方法（申请号：202312980664.8）

[4] 生物样本数据准确率的计算方法及装置（申请号：202311201738X）

[5] 数据处理方法、装置及电子设备（申请号：2023112527369）

[6] TMS个体化靶点定位方法及相关产品(申请号：202511547263.9)

[7] 一种基于便携式脑电的抑郁状态评估系统（申请号：202310842506.6）

[8] 一种运动康复处方的推荐方法及装置（申请号：202510577833.2）

[9] 一种抑郁症状的远程筛查方法、装置、电子设备和存储介质（202510560208.7），

[10] 一种医疗运动处方的生成方法、装置、电子设备和存储介质（申请号：202510560026.X）

[11] TMS个体化靶点定位方法及相关产品（申请号：202511547263.9）

[12] 一种基于单通道脑电信号的抑郁双相分类方法、设备及程序产品. 首都医科大学附属北京安定医院（申请号:202510691565.7）